Item 5.02 Departure of Directors or Certain Officers; Election of Directors;

Appointment of Certain Officers; Compensatory Arrangements of Certain

Officers.

As previously disclosed, Dr. Uwe Schramm, Altair Engineering Inc.'s (the "Company") former Chief Visionary Officer, notified the Company that he would be stepping down from his position as Chief Visionary Officer, effective June 30, 2022, and that he would cease to be employed by the Company and its subsidiaries, effective December 31, 2022 (the "Separation Date"). In connection with his retirement, Dr. Schramm and the Company entered into an Employment Separation and General Release Agreement, dated as of December 30, 2022 (the "Separation Agreement").

The Separation Agreement sets forth the terms of Dr. Schramm's compensation related to his separation, as approved by the Compensation Committee of the Board of Directors of the Company, and includes the following compensation to be paid to Dr. Schramm:



         •   an amount equal to $150,000 payable in biweekly installments for six
             consecutive months from the Separation Date;



         •   his earned and unpaid 2022 performance bonus, which shall be paid to
             Dr. Schramm at the time such executive bonuses for 2022 performance
             are payable to other executives of the Company;



         •   if elected by Dr. Schramm, COBRA continuation coverage for medical,
             dental, and vision and other employee benefit programs through
             June 30, 2023;



         •   an amount equal to $10,240.38 for 71 hours of accrued and unpaid paid
             time off; and



         •   accelerated vesting of 26,557 stock options and 2,364 restricted stock
             units, which reflects the extent that such stock options and
             restricted stock units would have vested if Dr. Schramm remained
             employed with the Company through December 31, 2023.

The Separation Agreement also provides that all stock options granted to Dr. Schramm will be amended to extend the amount of time Dr. Schramm has to exercise such stock options following termination of his employment from 90 days after the Separation Date to 270 days after the Separation Date (but in no event later than the original expiration date applicable to such stock options), subject to earlier termination in accordance with the Company's 2017 Equity Incentive Plan and the applicable grant agreement evidencing the stock options.

The foregoing payments are subject to Dr. Schramm not later revoking the Separation Agreement, as permitted thereunder. The Separation Agreement contains non-solicitation, non-compete, non-disparagement and confidentiality covenants from Dr. Schramm.

In addition, on January 1, 2023, the Company and Dr. Schramm intend to enter a consulting agreement with an initial one-year term, unless mutually extended by the parties, pursuant to which Dr. Schramm will provide services to the Company in exchange for payments of $10,000 per fiscal quarter.

--------------------------------------------------------------------------------

The foregoing description of the Separation Agreement is qualified in its entirety by reference to the full text of the Separation Agreement, a copy of which is filed herewith as Exhibit 10.1 and is incorporated by reference herein.

Item 9.01 Financial Statement and Exhibits.





10.1      Employment Separation and General Release Agreement, dated December 30,
        2022, by and between Dr. Uwe Schramm and the Company.

104     Cover Page Interactive Data File (embedded within the Inline XBRL
        document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses